Staar Surgical Co: Form 10-K for the period ended Jan 2, 2026
Filed with the SEC on Mar 3, 2026 and accepted by EDGAR at Mar 3, 2026, 15:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-01-02. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-12-28 to 2026-01-02 | $239.4m | us-gaap:Revenues |
| Cost of revenue | 12 months2024-12-28 to 2026-01-02 | $57.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2024-12-28 to 2026-01-02 | $182.4m | us-gaap:GrossProfit |
| Research and development | 12 months2024-12-28 to 2026-01-02 | $40.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2024-12-28 to 2026-01-02 | $274.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-12-28 to 2026-01-02 | −$91.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2024-12-28 to 2026-01-02 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-12-28 to 2026-01-02 | −$80.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-12-28 to 2026-01-02 | −$1.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-12-28 to 2026-01-02 | −$1.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-12-28 to 2026-01-02 | 49,568,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-12-28 to 2026-01-02 | −$34.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-12-28 to 2026-01-02 | $5.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2024-12-28 to 2026-01-02 | $6.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2026-01-02 | $153.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-01-02 | $311.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-01-02 | $451.7m | us-gaap:Assets |
| Current liabilities | At period end2026-01-02 | $68.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-01-02 | $107.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-01-02 | $344.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000718937-26-000004. Last ingested by Listed: Oct 27, 2026, 17:30 ET. Listed shows no prices and gives no investment advice.